Table 1.
Baseline characteristics of the monocentric cohort at the start of bDMARD therapy, comparison between switchers and non-switchers
| Characteristics | Non-switchers (N = 147) | Switchers (N = 117) | p value |
|---|---|---|---|
| Female sex | 48 (32.65%) | 69 (58.97%) | < 0.0001 |
| Age (years) | 56.0 (46.0–65.0) | 57.0 (49.0–65.0) | 0.06 |
| Psoriatic arthritis duration (years) | 15.0 (10.0–22.0) | 15 (10.0–21.0) | 0.94 |
| Polyarticular arthritis | 35 (23.81%) | 42 (35.89%) | 0.048 |
| Mono/oligoarticular arthritis | 61 (41.50%) | 54 (46.15%) | 0.82 |
| Axial involvement | 42 (28.57%) | 38 (32.48%) | 0.95 |
| Psoriasis duration (years) | 25.0 (17.0–36.0) | 24.0 (15.0–34.0) | 0.67 |
| Family history | 9 (6.12%) | 14 (11.96%) | 0.07 |
| Psoriasis | 127 (86.39%) | 102 (87.18%) | 0.73 |
| Inflammatory bowel disease | 1 (0.68%) | 3 (2.56%) | 0.22 |
| Uveitis | 4 (2.72%) | 0 (0%) | 0.11 |
| Tender joints (66/68 joint count) | 5.0 (2.0–8.0) | 4.0 (2.0–8.0) | 0.44 |
| Swollen joints (66/68 joint count) | 2.0 (0.0–4.0) | 2.5 (0.0–6.0) | 0.60 |
| VAS pain 0–10 | 7.0 (5.3–8.0) | 7.0 (5.0–7.6) | 0.90 |
| VAS global health 0–10 | 6.0 (4.5–7.0) | 6.5 (5.0–8.0) | 0.35 |
| CRP (mg/L) | 6.0 (3.0–15.5) | 5.5 (2.9–12.0) | 0.37 |
| ESR (mm/h) | 17.0 (8.0–34.0) | 19.0 (9.0–36.0) | 0.42 |
| DAPSA | 20.2 (15.1–27.9) | 18.9 (15.3–25.7) | 0.67 |
| Leeds Enthesitis Index (0–6) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.69 |
| Dactylitis (presence/absence) | 18 (12.24%) | 15 (12.85%) | 0.23 |
| HAQ | 0.5 (0.25–1.0) | 0.62 (0.25–1.5) | 0.046 |
| PASI 0–72 | 1.0 (0.3–3.0) | 1 (0.0–2.7) | 0.047 |
| Smoking | |||
| Non-smokers | 91 (61.90%) | 83 (70.94%) | 0.46 |
| Ever smokers | 56 (38.10%) | 34 (29.06%) | |
| BMI | 25.3 (22.9–27.7) | 25.4 (23.4–27.6) | 0.86 |
| Updated Charlson Comorbidity Index | 1 (0–3) | 1 (0–7) | 0.79 |
| Association therapy with a csDMARDs | 56 (38.10%) | 39 (33.33%) | 0.61 |
| First-line biological drug | |||
| Anti-TNFα | 120 (81.63%) | 106 (90.59%) | 0.75 |
| Ustekinumab | 15 (10.20%) | 8 (6.84%) | 0.88 |
| Secukinumab | 12 (8.16%) | 3 (2.56%) | 0.68 |
Significant results are highlighted in bold. Categorical variables are shown as number (%). Continuous variables are shown as medians and interquartile range. p ≤ 0.05 (between non-switchers vs. switchers)
VAS visual analogue scale, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAPSA Disease Activity in PSoriatic Arthritis, HAQ Health Assessment Questionnaire, PASI Psoriasis Area and Severity Index, BMI body mass index, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, TNFα tumor necrosis factor α